Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge.
Using surveys to collect various viewpoints on eConsent from ethics, sponsors, and vendors.
Findings from Florence Healthcare’s State of Clinical Trial Technology Industry survey about how clinical operations technology changed in 2020 and how they expected it to evolve throughout this year.
DCTs, data, and analytics are all areas that could be impacted in the near future.
Companies share their experience in future-proofing clinical data technology.
The era of big pharma as product-first companies must end, as services become the larger priority.
While underreported, ADR data offers significant value to the drug development value chain to refine the predictive capability and stability, and provide enhanced patient safety.
By decentralizing trials whenever feasible, sites can decrease patient burden, clinops workload, and the number of on-site participants.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Artificial intelligence may find a home in clinical trials and manufacturing in the coming years, but privacy, cyber security, and determining who owns the intellectual properties could pose challenges.
A top-down analysis of the decentralized trial model’s benefits and impact on the industry.
Promising scientific advances are pacing oncology drug development.
The adaptability and innovative capacity of CROs highlighted in EUCROF survey.
Harnessing advances in digital health technologies for a more precision-measured approach.
Growing availability of RWD leads new drug development process.
Webinar Date/Time: Tue, Tue, Nov 28, 2023 11:00 AM EST
Findings from a Tufts study examining the effects of COVID-19 on clinical trials.
The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating evidence in broader, more representative patient populations.
Series Part 3—Methods for early detection of risk and summary.
Strategies for sponsors in navigating the European Union's new health technology assessment regulation.
Bolstered by the recently approved S7B/E14 Q&A document, early-stage concentration-QTc analysis is emerging as a standard for assessing cardiac safety.
Lessons learned during the pandemic from University of Louisville.
The adaptability and innovative capacity of CROs highlighted in EUCROF survey.
Siloed systems can make it difficult to marry data to support timely and informed decision-making and optimize clinical trial operations.
Which new developments can help jump-start breakthroughs in immuno-oncology research? Understand the key scientific drivers, read peer-reviewed research, and get actionable ideas that can spur innovation in this must-read paper for clinical leaders.
Higher costs headline list of new challenges faced by CROs and sponsors.